Gastrointestinal Infection Testing Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The Global Gastrointestinal Infection (GI) Stool Testing Market is Segmented by Product Type (Instrument and Reagent), Test Type (Occult Blood Test, Ova and Parasites Test, Bacteria Test, Fecal Biomarkers Test, and Other Test Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecasts are provided in terms of value (USD million) for all the above segments.

Home right-chevron-icon Market Analysis right-chevron-icon Healthcare Research right-chevron-icon Medical Devices Research right-chevron-icon Diagnostic Devices Research right-chevron-icon Clinical Diagnostic Devices Research right-chevron-icon Clinical Diagnostic Laboratory Equipment Research right-chevron-icon Disease Specific Diagnostic Devices Research right-chevron-icon Gastroenterology Diagnostics Research right-chevron-icon GI Stool Examination Industry

GI Stool Testing Market Size

GI Stool Testing Market Summary
share button
Study Period 2018-2028
Market Size (2023) USD 476.37 Million
Market Size (2028) USD 653.90 Million
CAGR (2023 - 2028) 6.54 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

GI Stool Testing Market Major Players

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

GI Stool Testing Market Analysis

The GI Stool Testing Market size is expected to grow from USD 476.37 million in 2023 to USD 653.90 million by 2028, at a CAGR of 6.54% during the forecast period (2023-2028).

  • COVID-19 affected the GI stool testing market significantly. Various clinical studies were conducted to confirm the presence of coronavirus among the population. For instance, an article published in Frontiers in Medicine in May 2021 showed that Cepheid Xpert Xpress SARS-CoV-2 (tests with three gene targets (E, N2, and RdRP) assay was used for the accurate identification of viral RNA in stool samples. In addition, the Xpert Xpress SARS-CoV-2 test uses the GeneXpert benchtop equipment to enable qualitative detection of the virus in about 45 minutes.
  • The inclusion of stool PCR in the testing algorithm was anticipated to increase clinical sensitivity. Furthermore, as per the same source, the detection of viral RNA in stool was confirmed after 33 days, and stool PCR confirmed the diagnosis of SARS-CoV-2 in two individuals whose upper respiratory tract PCR results were negative. This has increased the utilization of stool testing techniques for confirming COVID-19 infection among the population, which is further anticipated to fuel the market growth over the forecast period. However, currently, as COVID-19 cases have been subsidized, the rising application of Gi stool testing leads to the stable growth of the market over the coming years.
  • The factors such as the growing burden of gastrointestinal diseases and rising preference for point-of-care tests are boosting the market growth. For instance, a 2022 update by Bower Cancer UK showed that bowel cancer is the 4th most common cancer, and approximately 43,000 people are diagnosed with bowel cancer every year in the United Kingdom. This is expected to increase the demand for stool DNA testing, which is used to screen for colon cancer in people with no symptoms, hence propelling the market growth.
  • Additionally, as per an article published in PLOS One in April 2021, it has been observed that the overall prevalence of hemorrhoids was higher in the male population in Northwest Ethiopia. The risk of having hemorrhoids was shown to be higher in people who were overweight and had constipation problems. Thus, the high prevalence of hemorrhoids among the population is anticipated to increase the need for a fecal occult blood test to early detect the disease and hence boost the market growth.
  • Furthermore, the rising product launches increase the availability of stool testing kits and products in the market, which in turn is anticipated to fuel the market growth. For instance, in June 2022, Prenetics Group Limited, one of the global leaders in genomic and diagnostic testing, launched a novel, non-invasive, at-home screening test, ColoClear by Circle (ColoClear), for detecting early signs of colorectal cancer in Hong Kong.
  • Therefore, owing to the factors such as the high burden of gastric cancer and other related diseases, the studied market is expected to grow over the forecast period. However, the high cost of instruments is expected to impede the growth of the GI stool testing market over the forecast period.

GI Stool Testing Market Trends

Reagent Segment is Expected to Witness Significant Growth in the GI Stool Testing Market Over the Forecast Period

  • The reagent segment is expected to witness significant growth in the GI stool testing market over the forecast period owing to the factors such as the rising prevalence of gastrointestinal diseases such as irritable bowel syndrome, GERD, and others, as well as rising demand for early detection of the diseases.
  • Reagents are substances that are often used for examining and analyzing. Reagents are expected to dominate the GI stool testing market with developing diagnostic technology. Chemiluminant assays are used as a diagnostic aid for the detection of gastrointestinal infections. It uses enzyme-labeled antibodies for detection, which is known to give an accurate diagnosis.
  • According to an article published in Microorganisms in June 2022, it was observed that microscopic examination of feces is still a common method for diagnosing intestinal parasite infections, which necessitates the use of reliable reagents and qualified personnel. In addition, as per the same source, the ready-to-use concentration methods for detecting parasite eggs in the ParaFlo tests (Eurobio Ingen) are expected to improve reagent traceability and manipulation ease. This is anticipated to boost the demand for reagents for detecting various gastrointestinal diseases, hence propelling segment growth.
  • Furthermore, stool testing is also beneficial for the early diagnosis of colon cancer, which is also expected to propel segment growth. For instance, as per an article published in the Clinical and Translational Gastroenterology in April 2022, the multitarget stool DNA test with fecal immunochemical test (sDNA-FIT) is recommended as a potential approach for colorectal cancer screening, in people aged 45 years and above and for those who are at average risk, in all significant United States guidelines. The sDNA-FIT analyzes 11 biomarkers, including human hemoglobin, NDRG4, and BMP3 aberrant methylation, KRAS point mutations, NDRG4 and BMP3 point mutations, and human hemoglobin. Hence the adoption of stool testing for various other GI-related diseases is anticipated to boost the market growth.
  • Moreover, in June 2022, Meridian Bioscience, Inc. launched two new sample-specific master mixes, Lyo-Ready Direct DNA qPCR Stool Mix and Lyo-Ready Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room temperature stabilization of diagnostic assay.
  • Therefore, owing to the factors such as the rising research studies and increasing adoption of reagents in stool testing, the studied segment is expected to grow over the forecast period.
GI Stool Testing Market: Estimated Number of New Colorectal Cancer Cases (in Thousands), United States, 2023

North America is Expected to Hold a Significant Share in the Market and is Expected to Witness the Same Over the Forecast Period

  • North America is expected to hold a significant share of the market and is expected to witness the same over the forecast period owing to the factors such as a higher incidence te of gastrointestinal diseases like colorectal cancer. For instance, according to 2023 statistics published by the ACS, about 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer cases are expected to be diagnosed in the United States in 2023. 
  • Also, as per an article published in the National Library of Medicine (NLM) in July 2022, gastroesophageal reflux disease (GERD) is one of the most widespread gastrointestinal conditions, affecting 20% of adults in Western countries such as the United States. In addition, the estimated prevalence of GERD in the US population ranges from 18.1% to 27.8%. Furthermore, per the data published by the Canadian Cancer Society, in May 2022, colorectal cancer is expected to be the fourth most diagnosed cancer in Canada. Nearly 24,300 Canadians were diagnosed with colorectal cancer, which represented 10% of all new cancer cases in Canada in 2022.
  • Furthermore, the rising company activities in developing innovative test kits and increasing product launches are also contributing to the market growth. For instance, in January 2023, Geneoscopy submitted a premarket approval application to FDA for its stool-based colorectal cancer screening test. Such initiatives may lead to the introduction of new products in the market in the near future and thus drives the growth of the market.
  • Therefore, owing to the factors such as the rising burden of colon cancer and GERD among the population and increasing product launches, the studied market is anticipated to augment the market growth over the forecast period.
GI Stool Testing Market - Growth Rate by Region

GI Stool Testing Industry Overview

The GI stool testing market is moderately fragmented in nature, with the presence of major players in the market. Collaborations, mergers, and acquisitions by companies related to GI stool testing are expected to boost market growth. Some of the companies which are currently dominating the GI stool testing market are bioMérieux SA, DiaSorin S.p.A, Cenegenics Corporation, Abbott Laboratories, Epitope Diagnostics Inc., Genova Diagnostics, Danaher Corporation (Beckman Coulter, Inc.), ScheBo Biotech AG, CTKBiotech Inc. Inc., and Cardinal Health.

GI Stool Testing Market Leaders

  1. Abbott Laboratories

  2. Genova Diagnostics

  3. bioMérieux SA

  4. Cardinal Health

  5. Danaher Corporation (Beckman Coulter, Inc.)

*Disclaimer: Major Players sorted in no particular order

GI Stool Testing Market Concentration

GI Stool Testing Market News

  • December 2022: Shineco, Inc. received United States Food and Drug FDA approval and a patent grant from the United States Patent and Trademark Office (US PTO) protecting its in-situ fecal specimen sampling device for the use of stool test sample collection. The product provides a massager-like fingertip swab, a collection tube, and a lid with a unidirectional sampling inlet.
  • June 2022: Prenetics Group Limited, in partnership with New Horizon Health, launched the ColoClear by Circle (ColoClear), a novel, non-invasive, at-home screening test for detecting early signs of colorectal cancer. The novel screening test uses advanced technology to detect multiple DNA biomarkers and blood cells in human stool.

GI Stool Testing Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Gastrointestinal Diseases

      2. 4.2.2 Rising Preference of Point of Care Test

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Instruments

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Product Type

      1. 5.1.1 Instruments

      2. 5.1.2 Reagents

    2. 5.2 By Test Type

      1. 5.2.1 Occult Blood Test

      2. 5.2.2 Ova and Parasites Test

      3. 5.2.3 Bacteria Test

      4. 5.2.4 Fecal Biomarkers Test

      5. 5.2.5 Other Test Types

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Danaher Corporation (Beckman Coulter, Inc.)

      3. 6.1.3 bioMerieux SA

      4. 6.1.4 Cardinal Health

      5. 6.1.5 Cenogenics Corporation

      6. 6.1.6 CTK Biotech Inc.

      7. 6.1.7 Genova Diagnostics

      8. 6.1.8 Epitope Diagnostics Inc.

      9. 6.1.9 ScheBo Biotech AG

      10. 6.1.10 Meridian Bioscience Inc.

      11. 6.1.11 DiaSorin S.p.A.

      12. 6.1.12 Quest Diagnostics Incorporated

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

GI Stool Testing Industry Segmentation

As per the scope of the report, GI stool testing involves the detection and analysis of any pathogens in the digestive tract using the stool as a sample. 

The GI stool testing market is segmented by product type (instrument and reagent), test type (occult blood test, ova and parasites test, bacteria test, fecal biomarkers test, and other test types), and geography(North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. 

The report offers the value (in USD million) for the above segments.

By Product Type
Instruments
Reagents
By Test Type
Occult Blood Test
Ova and Parasites Test
Bacteria Test
Fecal Biomarkers Test
Other Test Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

You can also purchase parts of this report. Do you want to check out a section wise price list?

GI Stool Testing Market Research FAQs

The GI Stool Testing Market size is expected to reach USD 476.37 million in 2023 and grow at a CAGR of 6.54% to reach USD 653.90 million by 2028.

In 2023, the GI Stool Testing Market size is expected to reach USD 476.37 million.

Abbott Laboratories, Genova Diagnostics, bioMérieux SA, Cardinal Health and Danaher Corporation (Beckman Coulter, Inc.) are the major companies operating in the GI Stool Testing Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).

In 2023, the North America accounts for the largest market share in GI Stool Testing Market.

GI Stool Testing Industry Report

Statistics for the 2023 GI Stool Testing market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. GI Stool Testing analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

GI Stool Testing Market Report Snapshots

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!